Skip to main content

Abbott Laboratories Diabetes Care revenue

  • ABT · NYSE
  • Pharmaceuticals
  • Health Care Equipment
  • S&P 500
$108.52+1.18%Close 13 Nov 2026 · Market value $187.6B

Diabetes Care revenue at Abbott Laboratories came to $2.2B for the quarter to 30 Sep 2026, up 6.2% from a year earlier.

As Abbott Laboratories reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 4 Nov 2026.

By quarter

$1.8BMar 2025$2.0BJun 2025$2.1BSep 2025$2.1BMar 2026$2.2BJun 2026$2.2BSep 2026
Abbott Laboratories Diabetes Care revenue, every reported period
Period endingDiabetes Care revenueChange on a yearFiled
30 Sep 2026$2.2Bup 6.2%4 Nov 2026
30 Jun 2026$2.2Bup 10.4%28 Jul 2026
31 Mar 2026$2.1Bup 13.8%29 Apr 2026
30 Sep 2025$2.1B—29 Oct 2025
30 Jun 2025$2.0B—30 Jul 2025
31 Mar 2025$1.8B—30 Apr 2025

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Abbott Laboratories: Core Laboratory revenue · Adult Nutritionals revenue · Key Emerging Markets revenue · Pediatric Nutritionals revenue · Cancer Diagnostics revenue · Rapid and Molecular revenue · Electrophysiology revenue · Vascular revenue · Rhythm Management revenue · Rapid Diagnostics revenue · Structural Heart revenue · Heart Failure revenue · Neuromodulation revenue · Point of Care revenue · Molecular revenue · COVID-19 Testing revenue · Medical Devices revenue · Diagnostic Products revenue · Nutritional Products revenue · Established Pharmaceuticals revenue · financial statements

Every KPI and segment of ABT, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.